In the last trading session, 1.83 million Cerus Corp (NASDAQ:CERS) shares changed hands as the company’s beta touched 1.25. With the company’s per share price at $1.73 changed hands at $0.06 or 3.59% during last session, the market valuation stood at $321.28M. CERS’s last price was a discount, traded about -49.71% off its 52-week high of $2.59. The share price had its 52-week low at $1.38, which suggests the last value was 20.23% up since then. When we look at Cerus Corp’s average trading volume, we note the 10-day average is 1.5 million shares, with the 3-month average coming to 1.58 million.
Analysts gave the Cerus Corp (CERS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.67. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CERS as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Cerus Corp’s EPS for the current quarter is expected to be -0.01.
Cerus Corp (NASDAQ:CERS) trade information
Instantly CERS was in green as seen at the end of in last trading. With action 1.76%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 12.34%, with the 5-day performance at 1.76% in the green. However, in the 30-day time frame, Cerus Corp (NASDAQ:CERS) is -4.42% down. Looking at the short shares, we see there were 7.8 million shares sold at short interest cover period of 6.35 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 42.33% from its current market value. According to analyst projections, CERS’s forecast low is 3 with 3 as the target high. To hit the forecast high, the stock’s price needs a -73.41% plunge from its current level, while the stock would need to soar -73.41% for it to hit the projected low.
Cerus Corp (CERS) estimates and forecasts
Data shows that the Cerus Corp share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -23.11% over the past 6 months, a 40.00% in annual growth rate that is considerably higher than the industry average of 12.00%. Year-over-year growth is forecast to reach 14.22% up from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 49.2M. 2 analysts are of the opinion that Cerus Corp’s revenue for the current quarter will be 47.45M. The company’s revenue for the corresponding quarters a year ago was 46.77M and 38.37M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 5.20%. The estimates for the next quarter sales put growth at 23.69%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 13.81%. The 2025 estimates are for Cerus Corp earnings to increase by 45.71%.
CERS Dividends
Cerus Corp is expected to release its next quarterly earnings report in February.
Cerus Corp (NASDAQ:CERS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.25% of Cerus Corp shares while 79.22% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 81.88%. There are 79.22% institutions holding the Cerus Corp stock share, with ARK INVESTMENT MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 10.9288% of the shares, roughly 19.9 million CERS shares worth $35.02 million.
BAKER BROS. ADVISORS LP holds the second largest percentage of outstanding shares, with 10.6965% or 19.48 million shares worth $34.28 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF . With 12.71 shares estimated at $21.99 million under it, the former controlled 6.84% of total outstanding shares. On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF held about 4.24% of the shares, roughly 7.88 shares worth around $13.63 million.